Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Patient Enrollment is a Critical Cost Driver in Phase 1 Clinical Trials

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Cutting Edge Information’s recent study of oncology trials revealed a strong correlation between number of patients and trial cost.

Both the number of patients and trial duration heavily impact a Phase 1 oncology trial’s total cost. The underlying force driving most costs is patient enrollment. As the time to reach full enrollment increases, the trial lasts longer and the cost of maintaining and staffing clinical sites rises.

Cutting Edge Information’s study “Oncology Clinical Trials: Drug Development Resources and Case Studies” discovered that for Phase 1 clinical trials, patient enrollment ranges from 25 to 97 patients with an average of 47.8 patients. As the patient pool increases, trial costs rise as well. Trials enrolling 40 or fewer patients report an average cost of $2.7 million. Trials enrolling more than 40 patients report an average cost of $7.6 million.

The Phase 1 oncology trials included in the study reported very little variability in the average planned and actual enrollments. The planned and actual enrollment numbers differ on average by fewer than two patients. Additionally, Phase 1 is the only phase to report small increases from planned to actual patient enrollment.

“Overall, the trend shows an increase in trial costs with increasing patient enrollment,” said Ryan McGuire research team leader at Cutting Edge Information. “The correlation coefficient between number of patients and trial cost is relatively strong. The expected patient enrollment helps a clinical program leader gauge the total cost of the trial. Higher enrollment generally requires more time, staff and site.”

“Oncology Clinical Trials: Drug Development Resources and Case Studies” features detailed oncology clinical development data including specific methods for best allocating resources in Phase 3. The research also highlights up-to-date metrics illustrating oncology clinical trial costs, one of the largest areas of study for the pharmaceutical industry. Drug companies that manufacture oncology medicines can use this report to:

•    Explore areas of higher activity for different types of cancer drug development.
•    Determine the cost per patient and other critical cost drivers for different types of oncology clinical trials.
•    Compare predicted and actual patient enrollment metrics of 30 oncology clinical trials from Phase 1 to Phase 3.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Product Launches Double Medical Affairs Spending
Cutting Edge Information’s new study finds that some companies increase medical affairs budgets by 100% preceding a product launch.
Tuesday, April 16, 2013
New Product Planning Spend Up to Half their Time on BD
A new survey of drug manufacturers found that new product planning teams dedicate upwards of 50% of their time on business development activities.
Tuesday, January 29, 2013
Increase in Pharmaceutical Companies Outsourcing Regulatory Affairs Budgets
A recent study by Cutting Edge Information shows outsourcing becoming more common for regulatory affairs tasks.
Thursday, January 10, 2013
Increase in Pharmaceutical Companies Outsourcing Regulatory Affairs Budgets
A recent study by Cutting Edge Information shows outsourcing becoming more common for regulatory affairs tasks.
Thursday, January 10, 2013
Increase in Pharmaceutical Companies Outsourcing Regulatory Affairs Budgets
A recent study by Cutting Edge Information shows outsourcing becoming more common for regulatory affairs tasks.
Thursday, January 10, 2013
Central and Eastern Europe Building Clinical Trial Success
Development teams benefit from tougher investigator standards and active patient populations, finds Cutting Edge Information.
Monday, February 14, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!